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Only three of the four thyroid hormone receptor (TR) isoforms, a1, b1,
and b2, bind thyroid hormone (TH) and are considered to be true TRs.
TRa2 binds to TH response elements on DNA, but its role in vivo is still
unknown. We produced mice completely deficient in TRa (TRao/o)
that maintain normal serum thyroid-stimulating hormone (TSH) con-
centration despite low serum thyroxine (T4), suggesting increased
sensitivity to TH. We therefore examined the effects of TH (L-3,3*,5-
triiodothyronine, L-T3) given to TH-deprived and to intact TRao/o mice.
Controls were wild-type (WT) mice of the same strain and mice
resistant to TH due to deficiency in TRb (TRb2/2). In liver, T3 produced
significantly greater responses in TRao/o and smaller responses in
TRb2/2 as compared with WT mice. In contrast, cardiac responses to
L-T3 were absent or reduced in TRao/o, whereas they were similar in
WT and TRb2/2 mice, supporting the notion that TRa1 is the domi-
nant TH-dependent TR isoform in heart. 5-Triiodothyronine (L-T3)
given to intact mice produced a greater suppression of serum T4 in
TRao/o than it did in WT mice and reduced by a greater amount the
TSH response to TSH-releasing hormone. This is an in vivo demon-
stration that a TR deficiency can enhance sensitivity to TH. This effect
is likely due to the abrogation of the constitutive ‘‘silencing’’ effect of
TRa2 in tissues expressing the TRb isoforms.
Thyroid hormone (TH) action is mediated through specificnuclear TH receptors (TRs) functioning as ligand-dependent
transcription factors that increase or decrease the expression of
target genes (1–3). There are two TR genes. The TRb locus
generates the b1 and b2 receptors by using two different promoters
and alternative splicing. The TRa locus encodes TRa1, a molecule
containing 410 aa, and three proteins that do not bind the ligand,
triiodothyronine (T3) (4–7) (GenBank accession no. AI322342).
TRa2, which results from an alternative splicing of the TRa
primary transcript, has 492 aa, the first 370 of which are identical
to TRa1. TRDa1 and TRDa2, molecules of approximately 154 and
237 aa, respectively, are generated from an internal promoter
located in intron 7 of the TRa locus (6). The function of TRa2,
which has a wide tissue distribution (8), and that of TRDa1 and
TRDa2, found mainly in brain, gut, and lung (6), are still unknown.
However, all have been shown to inhibit ligand-dependent trans-
activation of TRb and TRa1, a phenomenon termed the dominant
negative effect (6, 9–11, **).
The relative contribution of the two TR gene products in
mediating TH responses is poorly understood because of the
paucity of information regarding in vivo function. In vitro DNA
binding studies and functional assays in transfected cells have
generated conflicting results concerning the specific effect of TR
isoforms in gene regulation (12, 13). Interpretation is compli-
cated, however, because data are derived from artificial systems
using the overexpression of chimeric gene constructs that may
not be faithful models of events occurring in the intact animal.
The use of knockout mice that lack a particular TR isoform
provides a powerful tool for exploring the relative contribution
of each of the TR isoforms to the TH-mediated regulation of
various biological processes in different tissues. The specific role
of TRa was investigated indirectly in mice deficient in TRb (14).
Results suggested that TRa plays a major role in the regulation
of heart rate and basal metabolism (15). This conclusion was
confirmed and attributed to the TRa1 isoform (15).
Herein we examined the effects of TH deprivation and
treatment with L-3,39,5-triiodothyronine (L-T3) on the pituitary,
liver, and heart of homozygous mice deficient in all forms of TRa
(TRao/o). Compared with those of wild-type (WT) mice, the
pituitary gland and liver of TRao/o mice were more sensitive to
TH, whereas the same tissues of TRb knockout (TRb2/2) mice,
as previously shown, were resistant to TH. In contrast, the heart
of TRao/o mice was hyporesponsive to TH, indicating that TRa
is the predominant TR form expressed in this tissue. Given that
TRa1 knockout mice have no increased sensitivity to TH (16),
our results suggest that TRa2 exerts a dominant negative effect
in some tissues in vivo and that the absence of TRa2 enhances
sensitivity to TH.
Experimental Methods
Animal Procedures. As is the case with the TRa2/2 mouse (17), the
TRao/o mouse is deficient in both TRa1 and TRa2 encoded by
the TRa gene, but, in addition, it lacks the shorter transcripts
initiated from the internal promoter located in intron 7 (6).
However, the gene sequence for Rev-erbAa, the TR-related
protein encoded by the opposite strand of TRa (18, 19), remains
intact. In contrast to the TRa2/2 mice, the TRao/o mice survive
without rescue by TH treatment. They are fertile but have a
slightly slower growth rate. Thus the dose of L-T3 was adjusted
to the body weight (BW). Mice resistant to TH due to deletion
of the TRb gene (TRb2/2) (described in ref. 20) were used for
comparison. The TRb2/2 mice were derived after nine crossings
of TRb2/1 heterozygote with WT mice of the C57BLy6J strain
before inbreeding. TRao/1 mice were crossed four times with
WT mice of the same strain before heterozygotes were inter-
crossed. Breeding of the resulting homozygotes TRao/o and
TRa1/1 (WT) mice was used in the grouped experiments.
Mice were weaned in the fourth week after birth and were fed
rodent diet containing 0.53 ppm iodine (no. 5053; LabDiet,
Brentwood, MO) ad libitum and given tap water. All animal
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experiments were performed at the University of Chicago
according to protocols approved by the Institutional Animal
Care and Use Committee.
Because of sex and age differences in serum thyroid-
stimulating hormone (TSH) and thyroxine (T4) concentrations,
all mice were male and were 60–70 days old at the beginning of
each experiment. The BW of TRao/o mice (mean 6 SEM) of
18.4 6 0.4 g was significantly lower (P , 0.0001) than that of the
WT (23.4 6 0.5 g) and TRb2/2 mice (22.0 6 0.4 g). Experiments
were terminated by exsanguination under methoxyf lurane
(Pitman–Moore, Mundelein, IL) anesthesia. Livers were com-
pletely removed, weighed, cut into 0.2–0.5-g pieces, and frozen
on dry ice before storage at 285°C. Atria were removed and
heart ventricles were immediately frozen and stored at 285°C.
Induction of Hypothyroidism and Treatment with TH. TH deficiency
was induced in 10–14 male mice of each type (TRao/o, WT, and
TRb2/2) with a low-iodine diet containing 0.15% 5-propyl-2-
thiouracil (PTU), as described (21). On the 11th day, animals of
each type were split into two groups. One group received daily
i.p. injections of 2 mg of L-T3y100 g BWyday for 4 days, whereas
the other group received only the vehicle. The PTU diet was
given throughout the L-T3 and vehicle treatment period. The
concentration of L-T3 was confirmed by radioimmunoassay.
Experiments were terminated 12–16 h after the last injection. In
a separate experiment, groups of 4–5 mice were similarly treated
and blood was collected for serum T3 determination 24 h after
the penultimate L-T3 dose and at 2, 4, 8, and 16 h after the last
L-T3 injection. Note that separate animals were used for the 2-
and 8-h and 4- and 16-h posttreatment blood sampling.
In a separate experiment, L-T3 was given on the same schedule
to groups of mice of each type (10 WT and 7 TRao/o) with no prior
induction of hypothyroidism. Two incremental doses were given
consecutively as described (22), 0.2 mgy100 g BWyday, followed by
0.8 mgy100 g BWyday. Blood samples (approximately 300 ml) were
obtained from the tail vein before the treatment (baseline) and
12–16 h after the last injection of each incremental L-T3 dose.
The suppressive effect of TH on the response of TSH to
TSH-releasing hormone (TRH) was examined in WT and TRao/o
mice. Three groups of 5–6 animals of each type were given the two
doses of L-T3 or the vehicle only (basal) for 4 days. On the fifth day,
12–16 h after the last injection, blood samples were obtained before
and 15 min after the i.p. administration of 0.275 mg TRH.
Measurements in Serum Samples. Cholesterol levels were mea-
sured with an autoanalyzer as described. Serum TSH was
measured with a sensitive radioimmunoassay (23), and results
were expressed in bioassayable TSH units. Serum total T4 and T3
concentrations were measured by radioimmunoassays (Diagnos-
tic Products, Los Angeles). The sensitivities of these assays were
0.2 mg T4ydl and 20 ng T3ydl.
Heart Rate. Electrocardiograms were recorded under chloral hy-
drate anesthesia (4 mgy10 g BW i.p.) with mice placed in a water
bed maintained at 37°-38°C. A Hewlett–Packard monitoryterminal
(model 78534AA) with a chart speed of 25 mmys was used.
Tissue Analyses. T3 binding to liver nuclei was determined as
described (15). Pools of approximately 1 g of frozen liver pieces
from at least four animals of each type were used. All animals
had received the PTU diet for 14 days and were, thus, hypothy-
roid before liver collection. T3 binding affinity and maximal
binding capacity were determined by the method of Scatchard.
The former was corrected for DNA content.
Northern analyses were performed on RNA extracted from
tissues of individual animals. Total RNA was prepared by the
acid–guanidinium thiocyanate—phenol–chloroform method (24)
from livers and heart ventricles frozen 1–3 min after death and kept
at 285°C. Fifteen micrograms of total RNA was denatured and
fractionated by electrophoresis on 0.8% agarose gel, transferred
onto GeneScreen Plus (DuPontyNEN), using VacuGene (Amer-
sham Pharmacia). cDNA probes for iodothyronine type I 59-
deiodinase (59DI) (25), malic enzyme (ME) (26), and sarcoplasmic
reticulum calcium adenosine triphosphatase (SERCA2) [prepared
by reverse transcription–PCR with the sense (59-ACGATCTGT-
GCTCTGTGTAATGACTCT-39) and antisense (59-GCGCG-
TCGTTCACACCATCACCAGTCA-39) oligonucleotides] were
labeled with [g-32P]deoxycytidine triphosphate (specific activity 111
Bqymmol) (DuPontyNEN), using the Random Primed DNA La-
beling Kit (Roche Molecular Biochemicals). Hybridization and
subsequent washing procedures were carried out as described (27).
The quantity of mRNA on radiographs was measured with a
molecular imager (Bio-Rad).
To assess the uniformity in RNA transfer among samples,
hybridized membranes were reprobed with a cDNA comple-
mentary to rRNA. To correct the results of Northern blots, the
activity of rRNA probe hybridized to each lane was divided by
the average activity of rRNA for the entire group. These ratios
were used to correct the activity of the respective mRNA
abundance in each lane.
Data Presentation and Statistical Analysis. Values are reported as
mean 6 SE. P values were calculated by two-way ANOVA or
Student’s t test when comparisons were made within the same
genotype. Values corresponding to the respective limits of the assay
sensitivities were assigned to samples that measured below the
detectable range. Outliers were identified by a two-tailed test with
a significance level of ,0.05 (28, 29). No more than one outlier per
treatment group was removed. One TRb2/2 mouse did not achieve
a sufficient degree of hypothyroidism with the PTU diet, as
determined by a serum TSH level of 725 milliunitsyliter and a T4
of 5.3 mgydl, both 10-fold below and above the group means. All
data generated from this mouse were excluded. Statistics were










TRaoyo 22 6 3.5 3.29 6 0.09 96.1 6 7.2 358 6 22
(32) (31) (11) (23)
WT 25 6 3.0 3.76 6 0.10 83.6 6 3.0 470 6 6
(54) (47) (13) (43)
TRb2y2 136 6 18 7.78 6 0.33 142.3 6 12.4 522 6 8
(42) (37) (12) (48)
P (TRaoyo vs. WT) NS ,0.005 NS ,0.0001
P (TRaoyo vs. TRb2y2) ,0.0001 ,0.001 ,0.005 ,0.0001
The number of animals is in parentheses. NS, not significant.
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performed using STATVIEW 5.0 software (Abacus Concepts, Berke-
ley, CA).
Results
Thyroid Function Tests and Heart Rate at Baseline in TRao/o Mice as
Compared with WT and TRb2/2 Mice. Results of thyroid function
tests in untreated TRao/o are compared with those in WT and
TRb2/2 mice (Table 1). Despite the similar levels of circulating
TSH, TRao/o mice have significantly lower levels of total T4
(3.29 6 0.09 mgydl) compared with WT animals (3.76 6 0.10
mgydl, P , 0.005). As previously reported (14, 21), the TRb2/2
animals were resistant to TH and had increased levels of serum
T4 and T3 as well as TSH concentration. The mean basal heart
rate of TRao/o mice was significantly lower than that of WT mice,
a finding similar to that reported for mice lacking only the TRa1
isoform (16). The higher heart rate in TRb2/2 mice is as reported
previously (15, 30) and is consistent with the higher serum TH
levels in these animals.
Sensitivity of Serum TSH to the Feedback Regulation by TH. The
observation of a small, but significant, decrease in serum T4
concentration not associated with an alteration in basal serum TSH
values could be explained by reduced T4 binding to serum proteins,
mild hypothyroidism, or increased sensitivity to TH. To determine
the physiological significance of this observation, groups of mice
were given two incremental doses of L-T3, and the suppressive
effect on serum T4 was examined (Fig. 1). In addition, because the
basal serum TSH concentrations were too low for accurate mea-
surement of a decrease induced by L-T3, the TSH response 15 min
after the administration of TRH was determined (Fig. 2).
Treatment with 0.2 mg L-T3y100 g BW brought the serum T4
of TRao/o animals to 2.26 6 0.01 mgydl as compared with 3.01 6
0.11 mgydl in WT animals. This represents a reduction of 34.0 6
5.4% and 18.2 6 3.7%, respectively (P , 0.05). Treatment with
the higher dose of 0.8 mg L-T3y100 g BWyday for 4 more days
produced the same degree of serum T4 suppression in the two
types of mice (Fig. 1).
The response of TSH to TRH before TH treatment and its
suppression after the administration of the same two doses of
L-T3 are shown in Fig. 2. In animals not given L-T3, the
incremental TSH response to TRH was not different in TRao/o
mice compared with WT mice but was significantly lower in
TRb2/2 mice (P , 0.01). The higher dose of L-T3 suppressed the
TSH response by 77.3 6 5.7% in the TRao/o mice as compared
with 42.8 6 15.8% in WT mice (P 5 0.02). Collectively, these
data indicate that the feedback regulation of the pituitary–
thyroid axis of TRao/o mice is more sensitive to TH.
Of interest is the lower response of TSH to TRH at baseline
in TRb2/2 mice and the 49.2 6 26.3% paradoxical response in
these mice given the lower dose of L-T3. Similar findings were
reported 20 years ago with a comparable dose of L-T3 (31) given
to humans homozygous for TRb gene deletion (32).
Thyroid Function in TH-Deprived and TH-Treated Mice. To investigate
the role of TRa in the mediation of TH action, mice were studied
during TH deprivation and after supplementation with TH. The
dose of 2 mg L-T3y100 g BW (0.5 mgy25 g mouse) has been shown
to be effective in bringing the high serum TSH of hypothyroid
WT mice to normal, inducing metabolic effects, and producing
changes in liver (15, 21, 33). This investigative approach served
two purposes. First, it allowed determination of the tissue
responses of TRao/o mice to the same amount of TH as in WT
and TRb2/2 mice, which, under basal conditions, have different
serum concentrations of TH. Second, observations under the
conditions of TH deprivation and full replacement provided a
measure of the maximal physiological effect of TH.
The three genotypes that received the PTU diet only had
similar serum TSH, T4, and T3 levels (Table 2). L-T3 treatment
produced a greater suppression of serum TSH in the TRao/o mice
than in the WT animals, a difference that did not reach statistical
significance. As expected, the effect on TRb2/2 mice was lesser,
reflecting their decreased sensitivity to TH (Table 2).
Serum T3 concentrations achieved at different times after the
Fig. 1. Effect of TH on the feedback suppression of thyroid function. TRao/o
and WT mice were treated with two incremental doses of L-T3 each for 4
consecutive days. The decrease in serum T4 was expressed as a percentage of
the baseline values measured in the same mice before L-T3 treatment. Note the
greater suppression of T4 in TRao/o mice receiving the lower L-T3 dose. The
numbers of animals are in parentheses.
Fig. 2. Effect of TH on the TSH response to TRH. Groups of mice from the
three genotypes were treated for 4 days with two different doses of L-T3 or
with the vehicle only. TSH was measured before and 15 min after the admin-
istration of TRH. (A) TSH response to TRH in mice not given L-T3 (basal
response). (B) TSH responses to TRH in mice given L-T3, expressed as a per-
centage of the basal response. Note the paradoxical increase in TRb2/2 mice
receiving 0.2 mg L-T3y100 g BW and the greater suppressive effect of 0.8 mg
L-T3y100 g BW in TRao/o mice. In A, the number of animals in each group is in
parentheses. In B, data for each bar are derived from five or six animals. P
values indicated by * are differences in responses after L-T3 treatment as
compared with baseline. P values above bars were obtained by two-way
ANOVA of original numerical data.







administration of L-T3 were not different among the animals of
the three genotypes (Table 2 and Fig. 3).
Role of TRa in the Mediation of TH Action on Liver. Four known
markers of TH action were measured during TH deprivation and
after its supplementation as described above. L-T3 treatment
reduced the liver weight of WT and TRao/o mice but, as expected
(33), had no effect on the TRb2/2 animals. However, the
decrease was greater in TRao/o mice than in WT mice (P ,
0.005) (Fig. 4). TRao/o mice had a significantly higher reduction
in cholesterol after treatment with L-T3 as compared with WT
animals (P , 0.005). In contrast, and as expected (15), the
T3-mediated reduction in serum cholesterol was significantly
smaller in TRb2/2 mice (P , 0.0001) (Fig. 3).
59DI and ME are well characterized TH-responsive genes, the
transcriptional regulations of which have been extensively studied in
the rat (3, 34) and have been shown to undergo similar changes in
response to L-T3 in the mouse (15, 33). cDNAs of these two genes
were used to determine their mRNA content in the liver of TRao/o,
WT, and TRb2/2 mice by Northern blotting (Fig. 5). TH depriva-
tion abolished the ability to detect 59DI mRNA, even after pro-
longed exposure of the hybridized membranes. L-T3 treatment
produced a significantly greater increase in the abundance of the
mRNA of this enzyme in TRao/o mice as compared with WT
animals and a much smaller increase in TRb2/2 mice (P , 0.005
and , 0.0001, respectively). ME mRNA was also significantly (P ,
0.001) higher in TRao/o than in WT mice under L-T3 treatment.
Quantification of T3 Binding TR in Liver. To determine whether the
absence of TRa produces a compensatory increase in TRb, T3
binding studies were carried out in liver nuclei. The maximal T3
binding capacity in three separate experiments averaged 144
fmoly100 mg DNA for livers of WT animals. The corresponding
values in TRao/o and TRb2/2 mice were, respectively, 66% and
21% of the WT. These results indicate that deficiency in one of
the TR genes does not produce a compensatory increase in the
other. The relative contributions of TRb and TRa1 in the liver
of mice are similar to those reported in the rat (35).
Responses to TH of Heart Rate and TH-Responsive Genes Expressed in
Heart. Compared with baseline, TH deprivation decreased the
heart rate of both WT and TRb2/2 mice but had no effect on
TRao/o mice (358 6 22 vs. 335 6 20 beatsymin). L-T3 treatment
produced an increase in heart rate in WT and TRb2/2 mice
(89 6 8% and 66 6 4%) that was significantly higher in relative
magnitude than that in TRao/o mice (27 6 7%) (Fig. 6A).
Relative to the state of TH deprivation, L-T3 produced a
modest increase in cardiac SERCA2 mRNA in the WT and
TRb2/2 mice but not in the TRao/o mice (P , 0.001) (Fig. 6B).
Discussion
TH exerts its effects through interaction with specific nuclear
TRs, a1, b1, and b2 (36), that regulate the expression of target
genes by binding to cognate TH response elements, either as
homodimers or as heterodimers in association with retinoid X
receptors (37, 38). Because both TRa and TRb genes are
expressed in most tissues (8), either one or both can be impli-
cated in mediating in vivo the TH-dependent effects.
Fig. 3. Serum T3 concentrations at different times after the administration
of L-T3. Blood was obtained at the indicated times after the fourth i.p. dose of
L-T3 on the last day of the experiment. Values are not significantly different
among the three genotypes at each time point.
Fig. 4. Effect TH deprivation and L-T3 treatment on liver weight and serum
cholesterol. Groups of mice from the three genotypes were TH-deprived (PTU)
and then treated with TH (PTU 1 T3). Shown are measured values (Left) and
the percent changes induced by L-T3 treatment (Right). Note the greater
relative response to TH of TRao/o mice.
Table 2. Thyroid function tests in TRaoyo, WT and TRb2y2 mice after treatment with PTU and PTU1T3
PTU* PTU 1 T3†
TSH, mUyliter T4, mgydl T3, ngydl TSH, mUyL T4, mgydl T3, ngydl
TRaoyo 10,650 6 1,900 0.71 6 0.08 50 6 8 8 6 1.5 0.37 6 0.04 147 6 24
WT 8,700 6 1,150 1.04 6 0.07 48 6 4 18 6 7 0.38 6 0.05 114 6 23
TRb2y2 10,300 6 1,850 0.93 6 0.11 34 6 11 274 6 83 0.95 6 0.08 142 6 46
P (TRaoyo vs. WT) NS NS NS NS NS NS
P (TRaoyo vs. TRb2y2) NS NS NS ,0.01 ,0.0001 NS
NS, not significant.
*Fifteenth day of treatment with PTU.
†At the termination of the experiment, after 4 days of L-T3 treatment, except for the T3 value measured 24 h after the third and penultimate dose of L-T3.
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In our work, we sought to determine the role of TRa by
deleting all of its isoforms and examining the resulting tissue
responses to TH. Data were compared with those observed in
WT mice as well as animals deficient in both TRb isoforms,
manifesting signs of resistance to TH (20). The targeted muta-
tion in the TRao/o mouse inactivates completely not only the two
full-length TRa gene transcripts encoded by the main promoter,
but also the two shorter transcripts, TRDa1 and TRDa2, derived
from the promoter located in intron 7 (6). However, the gene
sequence for Rev-erbAa, the TR-related protein encoded by the
opposite strand of TRa (18, 19), remains intact.
Similar to the TRa1-deficient mice reported by Wikstro¨m et
al. (16), TRao/o mice, of the same age and sex, had significantly
lower serum T4 levels and heart rates than the respective WT
animals. However, in contrast to the TRa1-deficient mice, the
serum TSH concentrations of TRao/o mice were not different
from those of the WT animals, even after the analysis of more
than 30 serum samples of each genotype. The maintenance of a
normal serum TSH concentration despite a lower concentration
of T4 suggested increased sensitivity to TH. Indeed, adminis-
tration of the same dose of L-T3 to TRao/o and WT mice had a
greater suppressive effect on the serum T4 levels of the former,
indicating a greater inhibition of basal TSH, even though the
corresponding lower serum TSH values did not reach statistical
significance. Evidence for a reduced secretion of TSH in the
TRao/o mice was secured from the greater L-T3-induced sup-
pression of the TSH response to TRH. Together, these results
indicate that the feedback regulation of the pituitary–thyroid
axis of TRao/o mice is more sensitive to TH.
We then examined the sensitivity to TH in two peripheral
tissues, liver and heart, that express predominantly the TRb and
TRa genes, respectively (15, 39–40, ††). Studies were carried out
under the conditions of TH deprivation and TH supplementa-
tion, according to a previously tested and standardized protocol
(15, 21, 33). This protocol allows the comparison of tissue
responses to the same amount of TH in mice that under basal
conditions have different concentrations of TH. Moreover, the
comparison of measurements obtained under the conditions of
TH deprivation and full replacement increases the ability to
detect modest effects of the hormone. It should be noted that this
method does not achieve complete TH deficiency. However,
serum TSH and T4 concentrations were not significantly differ-
ent among mice of the three genotypes. Furthermore, similar
levels of serum T3 were achieved in all genotypes during L-T3
treatment.
Again TRao/o mice showed evidence for increased sensitivity
to TH in yet another tissue, the liver. L-T3 given to TH-deprived
animals reduced significantly more the liver weight and serum
cholesterol concentration in TRao/o as compared with WT mice.
The former reflects glycogen loss through TH-mediated catab-
olism and the latter, TH-induced stimulated transcription of
low-density lipoprotein receptor and cholesterol 7-a hydroxylase
genes, leading to enhanced removal of low-density lipoprotein
and cholesterol (41, 42). L-T3 also produced a greater increase
††Kinugawa, K., Minobe, W. A., Wood, W., Ridgway, C. E., Lowes, B. D., Baxter, J. D., Riberio,
R. C. J., Long, C. S. & Bristow, M. R. (1999) Circulation 100, Suppl. 18, I–507 (abstr.).
Fig. 5. Effect of TH deprivation and L-T3 treat-
ment on the expression of TH-regulated genes in
liver. Mice from the three genotypes were TH-
deprived (PTU) and then treated with TH (PTU 1
L-T3). Liver RNAs were analyzed for their abun-
dance in specific mRNAs by Northern blotting.
Radioautographs of membranes hybridized with
the two labeled cDNA probes (only five consecu-
tive animals of each group) are shown on the left,
and the percent changes induced by L-T3 are plot-
ted on the right. The membrane with RNA from
TRao/o and the corresponding WT mice was ex-
posed for 3 days (¶); those with RNA from the
TRb2/2 and another set of RNAs from the same WT
mice were exposed for 4 days. The same mem-
branes were rehybridized with an 18S rRNA
probe. Note the greater relative response to TH of
TRao/o mice.
Fig. 6. Effect of TH deprivation and L-T3 treatment on heart rate and the
expression of a TH-regulated gene in heart ventricle. Mice from the three
genotypes were TH-deprived (PTU) and then treated with TH (PTU 1 L-T3). (A)
Mean heart rates (Left) and the percentage changes induced by the treatment
with L-T3 (Right). (B) The radioautographs of membranes hybridized with the
SERCA2 probe (five consecutive animals of each group) are on the left, and the
percentage changes induced by L-T3 are plotted on the right. The same
membranes were rehybridized with an 18S rRNA probe. Note the reduced
responses of SRECA2 to L-T3 in TRao/o mice.







in the two TH-inducible liver mRNAs, 59DI and ME (26, 34, 43,
44), in TRao/o than in WT animals. It is of interest to note that
under the current experimental conditions, TH deprivation
reduced the expression of 59DI mRNA to undetectable levels in
animals of the three genotypes, whereas the reduction in ME
mRNA was less pronounced. As is the case with the up-
regulation of the pituitary TSH gene (20, 21, 45), down-
regulation of the liver 59DI gene, during TH deprivation, does
not appear to require the presence of TR.
TRao/o mice have a significant reduction in heart rate, which
increased with the administration of L-T3, as previously reported
for TRa1 knockout mice (16). Of interest is our finding that, in
contrast to the WT and TRb2/2 mice, the heart rate of TRao/o
mice did not change significantly during TH deprivation. This
observation suggests that in absence of TRa the heart rate is in
the hypothyroid range but still can be increased by TH, probably
through the residual TRb. Nevertheless, this L-T3-induced in-
crease in the TRao/o mice was smaller in magnitude compared
with the WT and TRb2/2 mice. The effect of L-T3 on SERCA2
mRNA was abolished in TRao/o mice. Judging from the results
obtained with the TRb2/2 mice, the TH-mediated response of
SERCA2 is completely TRa-dependent.
The observations made in the TRb2/2 mice are in agreement
with those previously reported (15, 22) for TRb2/2 mice pro-
duced by a slightly different method of gene disruption (14). A
finding not previously reported in the TRb knockout mouse is
the significantly lower response of TSH to TRH at baseline and
the paradoxical increase of this response after the administra-
tions of the lower L-T3 dose. Although the reason for this
unexpected response cannot be explained, this same effect has
been reported in humans genotypically and phenotypically sim-
ilar to the TRb2/2 mice (31, 32) but not in humans with TH
resistance caused by a dominant negative mutant TRb (46).
Increased sensitivity of TRao/o mice to TH was demonstrated
in the pituitary and liver, both tissues expressing predominantly
the TRb isoform. These mice differ from the TRa1-deficient
mice that have persistent expression of TRa2 and, presumably,
TRDa2. Compensatory increases in TRb expression do not
appear to occur at the RNA and protein levels in brain and liver
of TRa1-deficient and TRao/o mice, respectively. Thus, the
increased sensitivity of TRao/o mice to TH cannot be explained
by a higher level of TRb gene expression as observed in livers of
mice overexpressing TRb (33). It is thus likely that the enhanced
responsiveness to TH in the TRao/o mouse is due to the
abrogation of the constitutive silencing mediated through TRa2.
This ligand-unresponsive TR has been shown to exert a weak
dominant negative effect in transfected cells (10, 11). The
ubiquitous expression of TRa2 and its presence in tissues with
predominantly TRb-mediated TH action are expected to atten-
uate the effect of TH, particularly when TH is present in small
amounts. The enhanced effect of TH should not be manifested
in tissues of TRao/o mice in which TH action is mediated
predominantly through TRa1, as is the case in the heart. It
should be noted that our data do not exclude the possible
contribution of TRa1 deficiency to the increased sensitivity to
TH, by removal of a weaker transactivator that normally com-
petes with the TRb. The loss of the TRDa isoforms has no effect
on the observed effects on liver and pituitary because they are
not expressed in these tissues‡‡. Proof that a deficiency in TRa2
is the basis for the observed hypersensitivity to TH in mice
completely deficient of TRa should be contained in the mouse
deficient in TRa2 only. Although such mice do exist (47), no
information is yet available regarding their precise phenotype.
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